Tirés à part : A. Bauquet
Remerciements et autres mentions :
Financement : aucun.
Liens d’intérêts : les auteurs sont salariés de Smart Immune.
Smart Immune is developing a platform for cellular therapies capable of rearming the immune system, enabling patients to fight cancer and infections. This platform, ProTcell, uses ex vivo cell culture technology to obtain T lymphoid progenitors in just seven days. These therapeutic cells from a donor have the capacity to repopulate and possibly regenerate the thymus, where they acquire a new polyclonal repertoire of T cell receptors within 100 days – instead of one to two years after regular blood (hematopoietic) stem cell transplantation. Currently being studied in Phase I/II trials in adult patients with high-risk hematological malignancies and in infants with severe combined immunodeficiencies, this thymus-based approach holds promise for accelerated immune reconstitution and improved clinical outcomes following allogeneic stem cell transplantation. Several complementary applications in immuno-oncology are being studied, such as the development of ProTcell cells armed with a CAR (chimeric antigen receptor). These allogeneic cell therapies are being considered in and outside the context of stem cell transplantation.